The spouse of a patient who experiences delusions asks the nurse, “Are there any circumstances under which the treatment team is justified in violating the patient’s right to confidentiality?” What is the nurse’s best response?

Choice A reason: Blocking norepinephrine at alpha-1 receptors inhibits vasoconstriction, reducing vascular tone. This disrupts baroreceptor-mediated blood pressure regulation, causing orthostatic hypotension when standing. The autonomic nervous system fails to compensate for positional changes, leading to dizziness and fainting, a common side effect of alpha-1 blockers like prazosin.

Choice B reason: Increased psychotic symptoms are linked to dopamine dysregulation, not alpha-1 receptor blockade. Norepinephrine blockade affects autonomic functions, not psychosis, which involves mesolimbic dopamine hyperactivity. This side effect is unrelated to alpha-1 receptors, making this option scientifically inaccurate for the described mechanism.

Choice C reason: Appetite disturbance is typically associated with serotonin or histamine receptor effects, not alpha-1 norepinephrine blockade. Norepinephrine at alpha-1 receptors regulates vascular tone, not appetite control, which involves hypothalamic signaling. This side effect is not a direct consequence of alpha-1 blockade, rendering this option incorrect.

Choice D reason: Hypertensive crisis results from excessive norepinephrine activity, often due to monoamine oxidase inhibitors, not alpha-1 receptor blockade. Blocking alpha-1 receptors causes vasodilation, lowering blood pressure, not raising it. This makes hypertensive crisis an unlikely side effect, contrary to the pharmacological mechanism of alpha-1 blockers.

Choice A reason: Serotonin modulates mood and anxiety but is not primarily linked to schizophrenia’s core symptoms. While serotonin imbalances contribute to depression, schizophrenia’s hallucinations and delusions stem from dopamine hyperactivity in the mesolimbic pathway, making serotonin an incorrect choice for this disorder’s pathophysiology.

Choice B reason: GABA inhibits neural activity, and its dysfunction is linked to anxiety or seizures, not schizophrenia’s positive symptoms. Schizophrenia involves dopamine excess in the mesolimbic pathway, not GABA deficits. GABA’s role is secondary, making it an inaccurate choice for explaining hallucinations and delusions.

Choice C reason: Dopamine hyperactivity in the mesolimbic pathway causes hallucinations, delusions, and bizarre behavior in schizophrenia. Excess dopamine signaling disrupts cognitive and perceptual processes, leading to positive symptoms. Antipsychotics target D2 receptors to reduce these effects, confirming dopamine’s central role in schizophrenia’s pathophysiology.

Choice D reason: Acetylcholine is involved in memory and attention, not schizophrenia’s core symptoms. While cholinergic deficits occur in dementia, schizophrenia’s hallucinations and delusions are driven by dopamine dysregulation, not acetylcholine. This makes acetylcholine an incorrect choice for the neurotransmitter associated with these symptoms.